Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK plus PD-1 antibody in anaplastic thyroid cancer
ChiCTR2500098554Phase 2Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Mar 2025
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NKG2D CAR NK cells and PD-1 Monoclonal Antibody in anaplastic thyroid cancer (ATC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Tolerance at day 28, Safety at day 28 and 5 more. Started Mar 2025; status: recruiting.
02
Drugs
NKG2D CAR NK cellsPD-1 Monoclonal Antibody
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on ChiCTR2500098554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098554.